176 related articles for article (PubMed ID: 35877999)
1. Avapritinib for advanced systemic mastocytosis.
Gotlib J; Reiter A; DeAngelo DJ
Blood; 2022 Oct; 140(15):1667-1673. PubMed ID: 35877999
[TBL] [Abstract][Full Text] [Related]
2. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
Shomali W; Gotlib J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
[TBL] [Abstract][Full Text] [Related]
3. Avapritinib for Systemic Mastocytosis.
Bose P; Verstovsek S
Expert Rev Hematol; 2021 Aug; 14(8):687-696. PubMed ID: 34289787
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.
Reiter A; Schwaab J; DeAngelo DJ; Gotlib J; Deininger MW; Pettit KM; Alvarez-Twose I; Vannucchi AM; Panse J; Platzbecker U; Hermine O; Dybedal I; Lin HM; Rylova SN; Ehlert K; Dimitrijević S; Radia DH
Blood Adv; 2022 Nov; 6(21):5750-5762. PubMed ID: 35640224
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.
DeAngelo DJ; Radia DH; George TI; Robinson WA; Quiery AT; Drummond MW; Bose P; Hexner EO; Winton EF; Horny HP; Tugnait M; Schmidt-Kittler O; Evans EK; Lin HM; Mar BG; Verstovsek S; Deininger MW; Gotlib J
Nat Med; 2021 Dec; 27(12):2183-2191. PubMed ID: 34873347
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.
Gotlib J; Reiter A; Radia DH; Deininger MW; George TI; Panse J; Vannucchi AM; Platzbecker U; Alvarez-Twose I; Mital A; Hermine O; Dybedal I; Hexner EO; Hicks LK; Span L; Mesa R; Bose P; Pettit KM; Heaney ML; Oh ST; Sen J; Lin HM; Mar BG; DeAngelo DJ
Nat Med; 2021 Dec; 27(12):2192-2199. PubMed ID: 34873345
[TBL] [Abstract][Full Text] [Related]
7. The new tool "
Shomali W; Gotlib J
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):127-136. PubMed ID: 30504301
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis.
Lübke J; Naumann N; Kluger S; Schwaab J; Metzgeroth G; Evans E; Gardino AK; Lengauer C; Hofmann WK; Fabarius A; Cross NCP; Reiter A; Jawhar M
Leukemia; 2019 May; 33(5):1195-1205. PubMed ID: 30911112
[TBL] [Abstract][Full Text] [Related]
9. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
Reiter A; George TI; Gotlib J
Blood; 2020 Apr; 135(16):1365-1376. PubMed ID: 32106312
[TBL] [Abstract][Full Text] [Related]
10. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis.
Reiter A; Gotlib J; Álvarez-Twose I; Radia DH; Lübke J; Bobbili PJ; Wang A; Norregaard C; Dimitrijevic S; Sullivan E; Louie-Gao M; Schwaab J; Galinsky IA; Perkins C; Sperr WR; Sriskandarajah P; Chin A; Sendhil SR; Duh MS; Valent P; DeAngelo DJ
Leukemia; 2022 Aug; 36(8):2108-2120. PubMed ID: 35790816
[TBL] [Abstract][Full Text] [Related]
12. Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
Baird JH; Gotlib J
Curr Hematol Malig Rep; 2018 Oct; 13(5):407-416. PubMed ID: 30155614
[TBL] [Abstract][Full Text] [Related]
13. Kit Mutations: New Insights and Diagnostic Value.
Falchi L; Verstovsek S
Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
[TBL] [Abstract][Full Text] [Related]
14. Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms.
Gotlib J
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):34-46. PubMed ID: 36485158
[TBL] [Abstract][Full Text] [Related]
15. Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis.
Pilkington H; Smith S; Roskell N; Iannazzo S
Future Oncol; 2022 Apr; 18(13):1583-1594. PubMed ID: 35114819
[TBL] [Abstract][Full Text] [Related]
16. Response and progression on midostaurin in advanced systemic mastocytosis:
Jawhar M; Schwaab J; Naumann N; Horny HP; Sotlar K; Haferlach T; Metzgeroth G; Fabarius A; Valent P; Hofmann WK; Cross NCP; Meggendorfer M; Reiter A
Blood; 2017 Jul; 130(2):137-145. PubMed ID: 28424161
[TBL] [Abstract][Full Text] [Related]
17. Avapritinib in the Treatment of Systemic Mastocytosis: an Update.
Below S; Michaelis LC
Curr Hematol Malig Rep; 2021 Oct; 16(5):464-472. PubMed ID: 34580817
[TBL] [Abstract][Full Text] [Related]
18. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
19. Novel approaches to treating advanced systemic mastocytosis.
Gilreath JA; Tchertanov L; Deininger MW
Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
[TBL] [Abstract][Full Text] [Related]
20. KIT-mutated pediatric core-binding factor systemic mastocytosis-acute myeloid leukemia treated with avapritinib and decitabine.
Sheikh IN; AlQahtani S; Yin CC; McCall D; Cuglievan B; Ragoonanan D; Connors JS; Gibson A; Nunez C; Roth M; Ohanian M; Borthakur G; Garcia MB
Pediatr Blood Cancer; 2024 Apr; 71(4):e30898. PubMed ID: 38291730
[No Abstract] [Full Text] [Related]
[Next] [New Search]
